Want to see QTTB full AI Analyst Report?
QTTB Stock Chart & Stats
$16.32
-$0.23(-1.50%)
At close: 4:00 PM EDT
$16.32
-$0.23(-1.50%)
Day’s Range― - ―
52-Week Range$1.69 - $23.57
Previous CloseN/A
Volume178.84K
Average Volume (3M)430.05K
Market Cap
$330.44M
Enterprise Value$158.19
Total Cash (Recent Filing)$106.27M
Total Debt (Recent Filing)$5.30M
Price to Earnings (P/E)4.0
Beta0.27
Next Earnings
Nov 05, 2026EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.79
Shares Outstanding29,769,466
10 Day Avg. Volume409,966
30 Day Avg. Volume430,049
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.97
Price to Sales (P/S)0.76
P/FCF Ratio-1.22
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$41.00Price Target Upside151.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.46
Revenue Forecast (FY)$400.00K
Bulls Say, Bears Say
Bulls Say
Positive Phase 2a Clinical DataThe Phase 2a results provide meaningful evidence of clinical activity and favorable tolerability for bempikibart in severe alopecia areata. A registration-directed program and possible expansion into additional patient groups could broaden the opportunity if later-stage development confirms durability and safety.
Manageable Current LeverageThe current balance sheet provides greater financial flexibility than the company had in 2024, when leverage was materially higher. Low debt relative to equity can reduce interest and refinancing pressure, helping Q32 Bio direct more resources toward clinical development and other strategic priorities.
Strong Reported TTM ProfitabilityThe latest trailing period shows substantial reported revenue and net income, demonstrating that Q32 Bio can produce strong accounting results under its current financial profile. If this performance persists, it could improve funding flexibility and support continued investment in its development pipeline.
Bears Say
Persistent Cash BurnNegative operating and free cash flow indicate that the business is not currently self-funding, despite improved reported profitability. Continued cash burn can increase reliance on external financing and make clinical execution more vulnerable to changes in capital-market access over the next several quarters.
Volatile Earnings HistoryThe sharp variation in revenue and earnings across prior years weakens confidence that the latest profitable period represents a durable operating trend. Such instability makes forecasting more difficult and raises questions about the consistency and underlying quality of reported earnings as development progresses.
Clinical-stage Funding DependenceQ32 Bio remains dependent on advancing candidates rather than recurring sales from approved products, so its financial progress is tied to development outcomes and access to external capital. This structure can constrain strategic flexibility and amplify the consequences of setbacks in clinical execution.
Q32 Bio News
QTTB FAQ
What was Q32 Bio’s price range in the past 12 months?
Q32 Bio lowest stock price was $1.69 and its highest was $23.57 in the past 12 months.
What is Q32 Bio’s market cap?
Q32 Bio’s market cap is $330.44M.
When is Q32 Bio’s upcoming earnings report date?
Q32 Bio’s upcoming earnings report date is Nov 05, 2026 which is in 53 days.
How were Q32 Bio’s earnings last quarter?
Q32 Bio released its earnings results on Aug 05, 2026. The company reported -$0.44 earnings per share for the quarter, beating the consensus estimate of -$0.46 by $0.02.
Is Q32 Bio overvalued?
According to Wall Street analysts Q32 Bio’s price is currently Undervalued.
Does Q32 Bio pay dividends?
Q32 Bio does not currently pay dividends.
What is Q32 Bio’s EPS estimate?
Q32 Bio’s EPS estimate is -0.32.
How many shares outstanding does Q32 Bio have?
Q32 Bio has 29,769,466 shares outstanding.
What happened to Q32 Bio’s price movement after its last earnings report?
Q32 Bio reported an EPS of -$0.44 in its last earnings report, beating expectations of -$0.46. Following the earnings report the stock price went up 2.074%.
Which hedge fund is a major shareholder of Q32 Bio?
Currently, no hedge funds are holding shares in QTTB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Q32 Bio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$41.00 (151.23% Upside)
$41.00 (151.23% Upside)
Blogger Sentiment
Bullish
QTTB Sentiment 86%
Sector Average 62%
Sector Average 62%
Hedge Fund Trend
Increased
By 2.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $275.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 28.0%
Last 30 Days ▲ 28.4%
Last 30 Days ▲ 28.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
490.42%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
75.25%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Q32 Bio
Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished its Phase I clinical trial, targeting severe renal and other complement-driven conditions where patient needs are largely unmet, such as lupus nephritis, IgA nephropathy, C3 glomerulopathy, and ANCA-associated vasculitis. Additionally, Q32 Bio is advancing Bempikibart (ADX-914), a fully human monoclonal antibody antagonist against interleukin-7 receptor alpha. Currently in Phase II trials, Bempikibart aims to recalibrate adaptive immune responses by inhibiting signaling pathways involving interleukin-7 and thymic stromal lymphopoietin, offering potential treatment for atopic dermatitis and alopecia areata. Founded in 2017 and headquartered in Waltham, Massachusetts, Q32 Bio Inc. adopted its current name in April 2020, having previously operated as AdMIRx Inc.
QTTB Stock 12 Month Forecast
Average Price Target
$41.00
▲(151.23% Upside)
Technical Analysis
Tempest Therapeutics
―
PDS Biotechnology
―
Grace Therapeutics
―
CalciMedica
―
Senti Biosciences
―
Ownership Overview
6.57% Insiders
1.55% Mutual Funds
63.35% Other Institutional Investors
23.02% Public Companies and
Individual Investors